Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 12/14/2018
Entire Document
 
EX-99.1

Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: November 1, 2018 - November 30, 2018

MONTHLY OPERATING REPORT

File with Court and submit copy to United States Trustee within 20 days after end of month.

Submit copy of report to any official committee appointed in the case.

 

REQUIRED DOCUMENTS

   Form No.    Document
Attached
   Explanation
Attached
     Affidavit/Supplement
Attached
 

Schedule of Cash Receipts and Disbursements

   MOR-1    X      

Schedule of Disbursements by Debtor Entity

   MOR-1a    X      

Schedule of Debtor Bank Account Balances

   MOR-1b    X      

Schedule of Professional Fees and Expenses Paid

   MOR-1c    X      

Copies of bank statements

              Certification Attached  

Cash disbursements journals

              Certification Attached  

Bank reconciliation

              Certification Attached  

Statement of Operations

   MOR-2    X      

Balance Sheet

   MOR-3    X      

Status of Postpetition Taxes

              Certification Attached  

Copies of IRS Form 6123 or payment receipt

              Certification Attached  

Copies of tax returns filed during reporting period

              Certification Attached  

Summary of Unpaid Postpetition Debts

           

Summary of Unpaid Post Petition Accounts Payables

   MOR-4    X      

Accounts Receivable Aging

   MOR-5    X      

Debtor Questionnaire

   MOR-5    X      

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

 

/s/ Thomas P. Lynch

   

12 DEC 2018

Signature of Authorized Individual*     Date

Thomas P. Lynch

   

Chief Administrative Officer & General Counsel

Printed Name of Authorized Individual     Title of Authorized Individual

 

*

Authorized individual must be an officer, director or shareholder if debtor is a corporation; a partner if debtor is a partnership; a manager or member if debtor is a limited liability company.

Notes:

The last four digits of Debtor’s federal tax identification number are (8822). The Debtor’s mailing address for purposes of this chapter 11 case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.


UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

CERTIFICATION REGARDING POST-PETITION BANK ACCOUNT

RECONCILIATIONS, CASH DISBURSEMENT JOURNALS AND

COMPLIANCE AND PAYMENT OF POST-PETITION TAXES

I, Thomas Lynch, Chief Administrative Officer & General Counsel, of Orexigen Therapeutics, Inc. (the “Debtor”) hereby certify the following:

1. Attached to MOR-1 is a listing of the Debtor’s bank accounts, by account number, and the opening and closing balances. These accounts are reconciled monthly in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

2. Cash disbursement journals are maintained in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

3. To the best of my knowledge and belief, the Debtor is current on all post-petition taxes, and no post-petition tax amounts are past due.

 

/s/ Thomas P. Lynch

   

12 DEC 2018

Thomas Lynch     Date
Chief Administrative Officer & General Counsel    


UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

Notes to Monthly Operating Report

Debtor in Possession Financial Statements

The financial statements and supplemental information presented in this Monthly Operating Report (“MOR”) have been prepared using the Debtor’s books and records solely to comply with the monthly reporting requirements under the United States Bankruptcy Code and those of the United States Trustee for Region Three.

The financial statements and supplemental information presented herein are unaudited, preliminary in nature, and may not comply with generally accepted accounting principles in the United States of America (“U.S. GAAP”) in all material respects. These preliminary unaudited financial statements and other information represent the Debtor’s good faith attempt to comply with the requirements of the United States Bankruptcy Code and those of the United States Trustee using the resources available. This information is limited in scope to the requirements of this report.

These preliminary unaudited financial statements have not been subject to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP, and upon application of such procedures, the Debtor believes that the financial information could be subject to changes, which could be material. Certain totals may not sum due to rounding.

All related tax implications are not currently reflected in the preliminary unaudited financial statements herein. The financial impact of potential tax and other adjustments on the accompanying preliminary unaudited financial statements cannot be determined at this time.

There may be adjustments to the opening balance sheet as of March 12, 2018 that will impact these accompanying preliminary unaudited financial statements. ASC 805 permits a one-year measurement period in which the opening balance sheet can be adjusted if additional information becomes available.

Liabilities Subject to Compromise

As a result of the commencement of the Debtor’s chapter 11 case, the payment of certain prepetition indebtedness of the Debtor is subject to compromise or other treatment under a plan of reorganization.

Reorganization Items

ASC 852 requires expenses and income directly associated with the Debtor’s chapter 11 cases to be reported separately in the income statement as reorganization items. Reorganization items include expenses related to legal advisory and representation services, and other professional consulting and advisory services. Reorganization costs also include adjustment to record debt at the estimated amount of the claim and an estimate of the loss on sale of assets which is pending a valuation.

Litigation

The Debtor is subject to lawsuits and claims that arise out of its operations in the normal course of business.

Prior to the petition date, the Debtor was the defendant to various legal proceedings, described in detail in the most recent publicly filed financial statements, which are stayed during the course of the chapter 11 bankruptcy proceedings.

There are uncertainties inherent in any litigation and appeal and the Debtor cannot predict the outcome. At this time the Debtor is unable to estimate possible losses or ranges of losses that may result from such legal proceedings described in detail in the most recent publicly filed financial statements, and it has not accrued any amounts in connection with such legal proceedings in the financial statements herein, other than attorney’s fees accrued prior to the petition date.

Sale Transaction

On April 23, 2018, the Debtor entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. (the “Buyer”) for the sale of substantially all of its assets through section 363 of the Bankruptcy Code. This transaction was subsequently approved by the Bankruptcy Court on June 28, 2018. On July 27, 2018, the Debtor closed the sale and transferred substantially all of its assets to the Buyer. As part of the sale, the Debtor entered into a transition services agreement for the post-closing period through the effective date of a Plan of Liquidation. The Debtors are currently in discussions with their stakeholders to develop and file a Plan of Liquidation in the near term.


In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: November 1, 2018 - November 30, 2018

MOR - 1

Consolidated Schedule of Cash Receipts and Disbursements (1)

For the Period: November 1, 2018 - November 30, 2018

(Unaudited)

 

           Cumulative  

$ USD ‘000s

   November 1, 2018 - November 30, 2018     Since Filing  

Beginning Cash Balance (Book)

   $ 29,014     $ 21,372  

Receipts

    

Operating Receipts

     —         64,084  

Miscellaneous Receipts

     72       71,226  
  

 

 

   

 

 

 

Total Receipts

     72       135,311  

Operating Disbursements

    

Payroll & Benefits / Contractors

     (31     (16,961

Inventory

     (572     (4,981

Manufacturing and Logistics

     —         (205

Gross to Net Disbursements

     —         (36,451

Marketing / Commercial Operations

     —         (16,236

Ordinary Course Professionals

     (9     (989

Rent / Facilities / Equipment

     —         (564

Insurance

     —         (364

IT / Utilities

     —         (376

Regulatory and Compliance

     —         (634

Other G&A

     (109     (1,309
  

 

 

   

 

 

 

Total Operating Disbursements

     (721     (79,070

Operating Cash Flow

     (649     56,241  

Reorganization Costs

    

DIP Loan Interest and Fees

     —         (44,480

US Trustee Fees

     —         (621

Restructuring Professional Fees

     (105     (10,001
  

 

 

   

 

 

 

Total Reorganization Costs

     (105     (55,102

Total Disbursements

   $ (826   $ (134,172
  

 

 

   

 

 

 

Lender Professional Fees

     (310     (2,160

Net Cash Flow

   $ (1,064   $ (1,022

DIP Draw - Cash

     —         7,600  
  

 

 

   

 

 

 

Ending Cash Balance (Book)

   $ 27,950     $ 27,950  

Notes:

 

(1)

The Schedule of Cash Receipts and Disbursements is presented on a book basis.


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR - 1a

Schedule of Disbursements by Debtor Entity (1)

For the Period: November 1, 2018 - November 30, 2018

(Unaudited)

 

$ USD ‘000s

Debtor         

   November 1, 2018 - November 30, 2018      Cumulative
Since Filing
 

Orexigen Therapeutics, Inc.

   $ 1,136      $ 136,332  
  

 

 

    

 

 

 

Total

   $ 1,136      $ 136,332  

Notes:

 

(1)

The Schedule of Disbursements is presented on a book basis.


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: November 1, 2018 - November 30, 2018

(Unaudited)

 

$ USD ‘000s

Debtor         

  

Bank

   Last Four Digits
Account No.
    

Account Description

   Beginning
Balance
11/1/2018
     Ending
Balance
11/30/2018
 

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      6813      General checking    $ —        $ —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      3036      Sweep account      29,148        28,155  

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      7307      Utility adequate assurance(2)      10        —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      5177      Collateral      100        100  
           

 

 

    

 

 

 

Total Bank Account Balances

            $ 29,258      $ 28,255  
           

 

 

    

 

 

 

Notes:

 

(1)

The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.

(2)

The Utility account with Silicon Valley Bank was closed and the entire balance of $10,472 was transferred back to the General checking account. This transfer was completed on 11/12/2018.


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR - 1c

Schedule of Professional Fees and Expenses Paid

For the Period: November 1, 2018 - November 30, 2018

(Unaudited)

 

                          Month Ended 11/30/18     Cumulative Since Filing  

Payee

 

Category

  Payor     Date     Period Covered     Fees     Expenses     Fees     Expenses  

Retained Professionals

               

Hogan Lovells US LLP

  Debtor Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 8/31/2018         $ 2,189,780     $ 27,087  

Morris, Nichols, Arsht & Tunnell LLP

  Debtor Local Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 8/31/2018           721,973       18,605  

Ernst & Young, LLP

  Debtor Financial Advisor    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 8/31/2018           1,903,234       113,520  

Perella Weinberg Partners

  Debtor Investment Banker    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 7/27/2018           3,411,713       3,600  

Irell & Manella LLP

  Committee Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
    11/12/2018       3/12/2018 - 8/31/2018       30,670       5,453       659,730       1,671  

Berkeley Research Group LLC

  Committee Financial Advisor    

Orexigen
Therapeutics,
Inc.
 
 
 
    11/12/2018       3/27/2018 - 8/31/2018       53,676       767       240,358       2,102  

Elliott Greenleaf, P.C.

  Committee Local Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
    11/12/2018       3/27/2018 - 8/31/2018       2,983       —         96,864       481  

Kurtzman Carson Consultants LLC

  Claims Agent    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 6/30/2018           195,616       167,920  

Landis Rath & Cobb LLP

  Debtor Conflict Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
    11/12/2018       6/14/2018 - 9/30/2018       11,193       72       146,310       54  

Other Restructuring Professionals

               

Wilmington Trust, National Association

  DIP Administrative Agent    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 7/31/2018         $ 51,600     $ —    

Arnold & Porter Kaye Scholer LLP

  DIP Administrative Agent Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 7/27/2018           131,889       1,034  

Quinn Emanuel Urquhart & Sullivan, LLP

  DIP Lenders Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
    11/30/2018       3/12/2018 - 10/31/2018       245,980       7,496       999,266       12,140  

Brown Rudnick LLP

  DIP Lender Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
      2/15/2018 - 5/31/2018           147,048       1,497  

Whiteford Taylor Preston

  DIP Lenders Local Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
      3/12/2018 - 7/27/2018           203,253       2,141  

U.S. Bank, N.A.

  Indenture Trustee    

Orexigen
Therapeutics,
Inc.
 
 
 
    11/12/2018       3/1/2018 - 9/30/2018       56,786         632,020       3,040  

Duane Morris

  DIP Administrative Agent Secondary Counsel    

Orexigen
Therapeutics,
Inc.
 
 
 
      4/10/2018 - 7/27/2018           17,609       —    
         

 

 

   

 

 

   

 

 

   

 

 

 

Total

          $ 401,287     $ 13,789     $ 11,748,264     $ 354,892  


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR - 2

Statement of Operations

For the Period: November 1, 2018 - November 30, 2018

(Unaudited)

 

$ USD ‘000s

   November 1, 2018 - November 30, 2018     March 12 - November 30, 2018  

Net product sales(1)

   $ —       $ 28,050  

Cost of product sales(1)

     —         (6,367

Operating expenses:

    

Research and development(1)

     (9     (2,802

Selling, general and administrative(1)

     (230     (33,125

Amortization expense of intangible assets

     —         (2,987
  

 

 

   

 

 

 

Total operating expenses

     (239     (38,915
  

 

 

   

 

 

 

Loss from operations

     (239     (17,233

Other income/(expense):

    

Interest income

     56       871  

Refundable tax credit(2)

     —         —    

Interest expense(1)

     —         (63
  

 

 

   

 

 

 

Total other income (expenses)

     56       808  
  

 

 

   

 

 

 

Net loss

     (183     (16,424

Reorganization expenses(3)

     (798     (315,161

Net gain/(loss)

    
  

 

 

   

 

 

 
   $ (981   $ (331,586
  

 

 

   

 

 

 

Notes:

 

(1)

On July 27, 2018 the Debtor closed the sale and transferred substantially all of its assets to the Buyer. Activity in these accounts was the result of prior period accruals being trued up.

(2)

Refundable tax credit includes refundable alternative minimum tax as created by the Tax Cuts and Jobs Act. As the result of an audit, the income has been reclassed to 2017.

(3)

Reorganization expenses include the loss on sale of assets as well as the write up of the notes to the principle balance, the elimination of the debt discount and debt costs related to the 2013 debt. The loss on sale of assets is not final and pending the completion of a valuation of the non-debtor subsidiaries.


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR - 3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.  

$ USD ‘000s

   As of March 11, 2018      As of November 30, 2018  

Assets

     

Current assets:

     

Cash and cash equivalents

   $ 21,372      $ 27,950  

Accounts receivable, net

     19,203        —    

Inventory

     8,857        —    

Prepaid expenses and other current assets

     6,868        6,620  

Intercompany receivable(1)

     93,353        —    
  

 

 

    

 

 

 

Total current assets

     149,653        34,571  

Non-current assets:

     

Property and equipment, net

     543        —    

Investment in Subsidiary(1)

     19,000        —    

Intangible assets

     66,566        —    

Other long-term assets

     588        1,252  

Restricted cash

     100        100  
  

 

 

    

 

 

 

Total assets

   $ 236,450      $ 35,922  
  

 

 

    

 

 

 

Liabilities and Stockholders’ Equity

     

Current liabilities:

     

Accounts payable (2)

     925        740  

DIP loan

     —          —    

Accrued expenses

     3,921        3,375  
  

 

 

    

 

 

 

Total current liabilities:

     4,846        4,115  
  

 

 

    

 

 

 

Total liabilities not subject to compromise

     4,846        4,115  

Total liabilities subject to compromise

     110,381        243,143  

Series Z preferred stock

     3,343        —    

Stockholders’ equity (deficit)

     117,880        (211,336
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity (deficit)

   $ 236,450      $ 35,922  
  

 

 

    

 

 

 

Notes:

 

(1)

Investment in Subsidiary $19m reclassed from Intercompany Receivable at March 11, 2018 to properly align for reporting.

(2)

Accounts payable excludes all liabilities assumed by the purchaser under the terms of the Asset Purchase Agreement.


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR-4

Summary of Unpaid Post Petition Accounts Payables

As of November 30, 2018

(Unaudited)

 

$ USD ‘000s

                                         
     Number of Days Past Due  

Post Petition Accounts Payable Aging

       Current              0-30              31-60              61-90              Over 90              Total      

Post-Petition Accounts Payable (1)

   $ 315      $ 425      $ —        $ —        $ —        $ 740  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 315      $ 425      $ —        $ —        $ —        $ 740  

Notes:

 

(1)

The above figures represent post petition trade payables recorded in the Debtors’ subledger.


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR-5

Accounts Receivable Aging

As of November 30, 2018

(Unaudited)

 

$ USD ‘000s                                    

Accounts Receivable Aging

      Current             0-30 Days             31-60 Days             61-90 Days             91 Days +             Total      

Accounts Receivable, net

  $ —       $ —       $ —       $ —       $ —       $ —    
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
  $ —       $ —       $ —       $ —       $ —       $ —  

Debtor Questionnaire

 

Must be completed each month

  

      Yes      

  

      No      

1.   Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.       X
2.   Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.       X
3.   Have all post petition tax returns been timely filed? If no, provide an explanation below.    X   
4.   Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.    X   
5.   Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.       X


CERTIFICATE OF SERVICE

I, Tamara K. Mann, certify that I am not less than 18 years of age, and that service of the foregoing Monthly Operating Report for the Reporting Period November 1, 2018 – November 30, 2018, was caused to be made on December 13, 2018, in the manner indicated upon the party identified below.

VIA HAND DELIVERY

Attn: Timothy Fox, Esq.

Office of the United States Trustee

J. Caleb Boggs Federal Building

844 North King Street, Suite 2207

Wilmington, DE 19801

 

Dated: December 13, 2018    

                /s/ Tamara K. Mann

          Tamara K. Mann (No. 5643)